Interactions between antiepileptic and chemotherapeutic drugs

作者: Charles J Vecht , G Louis Wagner , Erik B Wilms

DOI: 10.1016/S1474-4422(03)00435-6

关键词:

摘要: Summary Cancer and epilepsy commonly co-occur, concomitant administration of antiepileptic (AEDS) chemotherapeutic drugs (CTDs) is necessary in many cases. Many are metabolised by the hepatic cytochrome P450 (CYP) isoenzyme system, coadministration AEDs CTDs can lead to clinically relevant interactions induction or inhibition enzymes shared metabolic pathways. These cause insufficient tumour seizure control unforeseen toxicity. Enzyme-inducing reduce effects taxanes, vinca alkaloids, methotrexate, teniposide, camptothecin analogues. Inhibition metabolism nitrosoureas etoposide valproic acid CTD Poor may result from combinations phenytoin with cisplatin corticosteroids, methotrexate. Increased toxicity occur when combined 5-fluorouracil. Use enzyme-inducing should be avoided patients cancer, particularly association chemotherapy. Generally, acid— although not free interactions—would agent first choice. Some newer system prove good alternatives.

参考文章(78)
Robert K. Sylvester, F. Bruce Lewis, Kenneth C. Caldwell, Michael Lobell, Robert Perri, Ronald A. Sawchuk, Impaired phenytoin bioavailability secondary to cisplatinum, vinblastine, and bleomycin. Therapeutic Drug Monitoring. ,vol. 6, pp. 302- 305 ,(1984) , 10.1097/00007691-198409000-00008
Steven A. Wrighton, Jeffrey C. Stevens, The human hepatic cytochromes P450 involved in drug metabolism. Critical Reviews in Toxicology. ,vol. 22, pp. 1- 21 ,(1992) , 10.3109/10408449209145319
Bhagavatula Moorthy, Padmavathi Sriram, Erika Randerath, Kurt Randerath, Effects of cytochrome P450 inducers on tamoxifen genotoxicity in female mice in vivo Biochemical Pharmacology. ,vol. 53, pp. 663- 669 ,(1997) , 10.1016/S0006-2952(96)00875-1
Moustapha Hassan, Gunnar �berg, Magnus Bj�rkholm, Inger Wallin, Mariette Lindgren, Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemotherapy and Pharmacology. ,vol. 33, pp. 181- 186 ,(1993) , 10.1007/BF00686213
Srikanth Nallani, Mary Genter, Pankaj Desai, Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel. Cancer Chemotherapy and Pharmacology. ,vol. 48, pp. 115- 122 ,(2001) , 10.1007/S002800100283
Stephen M. Dombrowski, Shailesh Y. Desai, Matteo Marroni, Luca Cucullo, Kris Goodrich, William Bingaman, Marc R. Mayberg, Ljiljana Bengez, Damir Janigro, Overexpression of Multiple Drug Resistance Genes in Endothelial Cells from Patients with Refractory Epilepsy Epilepsia. ,vol. 42, pp. 1501- 1506 ,(2001) , 10.1046/J.1528-1157.2001.12301.X
R. W. Fincham, D. D. Schottelius, Decreased phenytoin levels in antineoplastic therapy. Therapeutic Drug Monitoring. ,vol. 1, pp. 277- 283 ,(1979) , 10.1097/00007691-197901020-00009
S M Chang, J G Kuhn, J Rizzo, H I Robins, S C Schold, A M Spence, M S Berger, M P Mehta, M E Bozik, I Pollack, M Gilbert, D Fulton, C Rankin, M Malec, M D Prados, Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. Journal of Clinical Oncology. ,vol. 16, pp. 2188- 2194 ,(1998) , 10.1200/JCO.1998.16.6.2188
Jean-Guy Villemure, Nicolas de Tribolet, Epilepsy in patients with central nervous system tumors Current Opinion in Neurology. ,vol. 9, pp. 424- 428 ,(1996) , 10.1097/00019052-199612000-00005
Stuart A. Grossman, Vivian R. Sheidler, Mark R. Gilbert, Decreased phenytoin levels in patients receiving chemotherapy The American Journal of Medicine. ,vol. 87, pp. 505- 510 ,(1989) , 10.1016/S0002-9343(89)80605-9